Patient-level meta-analysis shows P2Y12 inhibitor monotherapy outperforms asiprin for CAD-related events
Compared with aspirin monotherapy, P2Y12 inhibitor monotherapy is associated with lower risks of cardiovascular death, myocardial infarction, and stroke in patients with coronary artery disease (CAD), mainly owing to a lower risk of myocardial infarction (MI) resulting in a reduced risk of adverse clinical events, a new meta-analysis reveals.